Eli Lilly Shifting Direction of Alzheimer’s Research

Eli Lilly is acquiring a diagnostic tool from Siemens, in efforts to shift the direction of research in Alzheimer’s, which has yielded little results in treating the amyloid plaque build-up in the brain, to fibrous bundles of protein tau.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s